Handelsavisen
prelaunch
Companies Healthcare 8049.HK
80
8049.HK HKEX Pharmaceuticals

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

HK$2,35
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,3B HKD
P/E
EV / Rev
Div yield
Op margin
29,5 %
ROE
11,8 %
Net margin
22,1 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.

Business. Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Jilin Province, China, and operates within the broader pharmaceuticals and medical research sector. It is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 8049.HK. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
11,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 8049.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 8049.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Jilin Province Huinan Changlong Bio-pharmacy Co Ltd (8049.HK) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in Jilin Province, China, and operates within the broader pharmaceuticals and medical research sector. It is primarily listed on the Hong Kong Stock Exchange under the ticker symbol 8049.HK. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Jilin Province Huinan Changlong Bio-pharmacy Co Ltd maintains a conservative capital structure with a price-to-book ratio of 0.8 and a debt-to-equity ratio of 0.0, indicating minimal leverage. The company's liquidity position is strong, with a current ratio of 1.3 and cash and equivalents of 143.1 million CNY, which supports operational flexibility. The market capitalization of 1.34 billion CNY and a price-to-earnings ratio of 6.76 suggest the stock is trading at a discount relative to earnings.

    The company's profitability is robust, with a return on equity of 11.78% and a return on assets of 7.45%, both exceeding the typical thresholds for the pharmaceutical industry. Gross profit of 757.67 million CNY and operating income of 265.85 million CNY reflect strong cost control and pricing power. However, the net income of 198.88 million CNY is lower than the gross profit, indicating some pressure on operating expenses or taxes.

    Geographic and segment exposure data is not available in the provided input, but the company's revenue of 901.87 million CNY is likely concentrated in its domestic operations given the lack of international revenue breakdown. The absence of detailed segment reporting limits the ability to assess diversification or growth drivers within the business.

    The company's growth trajectory is modest, with no specific revenue or earnings growth projections provided in the input data. Analyst estimates for the last actual EPS and revenue are 0.02 CNY and 97.28 million CNY, respectively, which are slightly below the reported figures, suggesting a stable but not rapidly growing business. The free cash flow of 96.17 million CNY and capital expenditure of -12.45 million CNY indicate that the company is generating positive cash flow and may be reducing investments in physical assets.

    Risk factors for the company are minimal, with low liquidity and dilution risks identified. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable. The absence of significant debt and the presence of substantial cash reserves reduce the likelihood of financial distress.

    Recent events and filings do not show any material changes in the company's operations or financial condition. The lack of recent significant events or disclosures suggests a stable and predictable business environment. The company's financial performance and risk profile remain consistent with its historical trends.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 1.3 and significant cash reserves.
    • Profitability metrics such as return on equity and return on assets are above industry norms.
    • The company's capital structure is conservative, with no long-term debt and a low debt-to-equity ratio.
    • Growth projections are limited, and the company appears to be maintaining a stable business model.
    • Risk factors are minimal, with no immediate liquidity or dilution concerns.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$2,35
    Market cap
    HK$1.34B
    Enterprise value
    HK$1.21B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    3.9x
    P / B
    0.8x
    P / Tangible book
    0.8x
    Tangible book
    HK$1.69B
    Net cash
    HK$137.6M
    Current ratio
    1.3
    Debt / equity
    0.0
    ROA
    7.4%
    ROE
    11.8%
    Cash conversion
    158.0%
    CapEx / revenue
    -1.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin29,5 %Best in class
    Net Margin22,1 %Above P75
    ROE11,8 %Above P75
    Capex / Rev-1,4 %Above P75
    D/E0,00Above P75
    Cash Conv1,58Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Jilin Province Huinan Changlong Bio-pharmacy Co Ltd Market data — financials · 2026-05-27
    • Jilin Province Huinan Changlong Bio-pharmacy Co Ltd Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    8049.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage